课题基金 / 基金详情

INTERLEUKIN 1 REDUCES GLYCOLYTIC UTILIZATION OF GLUCOSE BY PANCREATIC ISLETS

INTERLEUKIN 1 REDUCES GLYCOLYTIC UTILIZATION OF GLUCOSE BY PANCREATIC ISLETS
白细胞介素 1 减少胰岛对葡萄糖的糖酵解利用
批准号:
6118558
负责人:
ZHONGMIN ALEX MA
金额:
$0.08万
依托单位:
依托单位国家:
美国
项目类别:
财政年份:
1998
资助国家:
美国
项目状态:
已结题
起止时间:
1998-08-01 至 1999-07-31

项目摘要

项目成果

ZHONGMIN ALEX MA的其他基金

相似基金

相关文献

中文摘要
翻译
大鼠胰岛培养与白细胞介素-1(IL-1)结果 一氧化氮合酶诱导型亚型的上调 (iNOS)和一氧化氮(NO)的过度产生。 这与 可逆性抑制葡萄糖诱导的胰岛素分泌 和胰岛葡萄糖氧化,而这些作用是由 iNOS抑制剂NG-单甲基精氨酸(NMMA)。 IL-1还诱导 非酯化花生四烯酸在胰岛中的积累 NO依赖性机制,如同位素稀释质量所示 光谱法和一个可能解释这种影响, 涉及IL-1诱导的胰岛糖酵解通量的增强。 我们有 因此检测了IL-1对胰岛糖酵解利用的影响, 葡萄糖,并发现在含有IL-1的培养基中培养胰岛 5.5 mM葡萄糖导致胰岛葡萄糖利用的抑制 随后在6至18 mM的葡萄糖浓度下测量。 IL-1诱导的胰岛葡萄糖利用的抑制是 与胰岛葡萄糖激酶mRNA含量下降相关, 通过竞争性RT-PCR测定,并且在葡萄糖激酶蛋白中 合成,如通过免疫沉淀实验所确定的,并且所有 这些影响都被NMMA阻止了。 这些发现表明 IL-1可以下调胰岛葡萄糖激酶,这是主要的 胰岛葡萄糖传感器装置的组成部分,通过NO依赖性 机制 因为已知胰岛葡萄糖激酶水平的降低 导致一种类型的II型糖尿病,这些观察提高 增加胰岛NO水平的因素可能 有助于葡萄糖耐受不良的发展。
英文摘要
Culture of rat pancreatic islets with interleukin-1 (IL-1) results in up-regulation of the inducible isoform of nitric oxide synthase (iNOS) and overproduction of nitric oxide (NO). This is associated with reversible inhibition of both glucose-induced insulin secretion and islet glucose oxidation, and these effects are prevented by the iNOS inhibitor NG-monomethyl-arginine (NMMA). IL-1 also induces accumulation of nonesterified arachidonic acid in islets by an NO-dependent mechanism, as demonstrated by isotope dilution mass spectrometry and one potential explanation for that effect would involve an IL-1-induced enhancement of islet glycolytic flux. We have therefore examined effects of IL-1 on islet glycolytic utilization of glucose and find that culture of islets with IL-1 in medium containing 5.5 mM glucose results in suppression of islet glucose utilization subsequently measured at glucose concentrations between 6 and 18 mM. The IL-1-induced suppression of islet gluc ose utilization is associated with a decline in islet glucokinase mRNA content, as determined by competitive RT-PCR, and in glucokinase protein synthesis, as determined by immuno-precipitation experiments, and all of these effects are prevented by NMMA. These findings suggest that IL-1 can down-regulate islet glucokinase, which is the primary component of the islet glucose-sensor apparatus, by an NO-dependent mechanism. Because reductions in islet glucokinase levels are known to cause a form of type II diabetes mellitus, these observations raise the possibility that factors which increase islet NO levels might contribute to development of glucose intolerance.
期刊论文(0)
专著(0)
科研奖励(0)
会议论文
Development of DT-110 as an oral therapeutic for type 2 diabetes
  • 批准号:
    9046798
  • 项目类别:
  • 资助金额:
    $76.59万
  • 财政年份:
    2015
  • 负责人:
    ZHONGMIN ALEX MA
  • 依托单位:
Development of DT-109 as an oral therapeutic for type 2 diabetes
  • 批准号:
    8830889
  • 项目类别:
  • 资助金额:
    $22.5万
  • 财政年份:
    2015
  • 负责人:
    ZHONGMIN ALEX MA
  • 依托单位:
Development of DT-110 as an oral therapeutic for type 2 diabetes
  • 批准号:
    9146926
  • 项目类别:
  • 资助金额:
    $72.49万
  • 财政年份:
    2015
  • 负责人:
    ZHONGMIN ALEX MA
  • 依托单位:
PROTECTION OF PANCREATIC BETA-CELLS BY GROUP VIA PHOSPHOLIPASE A(2)
  • 批准号:
    8361459
  • 项目类别:
  • 资助金额:
    $0.83万
  • 财政年份:
    2011
  • 负责人:
    ZHONGMIN ALEX MA
  • 依托单位:
海外基金